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Aims. To determine the relationship between diabetic nephropathy and diabetic retinopathy on a population of type 2 diabetes
mellitus patients. Methods. A prospective ten-year follow-up population-based study. We determined differences between
estimated glomerular filtration rate (eGFR) using the chronic kidney disease epidemiology collaboration equation and urine
albumin to creatinine ratio. Results. Annual incidence of any-DR was 8.21± 0.60% (7.06%–8.92%), sight-threatening diabetic
retinopathy (STDR) was 2.65± 0.14% (2.48%–2.88%), and diabetic macular edema (DME) was 2.21± 0.18% (2%–2.49%). Renal
study results were as follows: UACR> 30mg/g had an annual incidence of 7.02± 0.05% (6.97%–7.09%), eGFR< 60ml/min/
1.73m2 incidence was 5.89± 0.12% (5.70%–6.13%). Cox’s proportional regression analysis of DR incidence shows that renal
function studied by eGFR< 60ml/min/1.73m2 was less significant (p = 0 04, HR 1.223, 1.098–1.201) than UACR≥ 300mg/g
(p < 0 001, HR 1.485, 1.103–1.548). The study of STDR shows that eGFR< 60ml/min/1.73m2 was significant (p = 0 02, HR
1.890, 1.267–2.820), UACR≥ 300mg/g (p < 0 001, HR 2.448, 1.595–3.757), and DME shows that eGFR< 60ml/min/1.73m2 was
significant (p = 0 02, HR 1.920, 1.287–2.864) and UACR≥ 300mg/g (p < 0 001, HR 2.432, 1.584–3.732). Conclusions. The UACR
has a better association with diabetic retinopathy than the eGFR, although both are important risk factors for diabetic retinopathy.
1. Introduction
Diabetic nephropathy (DN) and retinopathy (DR) are micro-
vascular complications of diabetes mellitus which share risk
factors, such as poor glycemia control and systolic hyperten-
sion. Their relationship has been the focus of our previous
studies, where we demonstrate good positive relationship of
microalbuminuria and macroalbuminuria in type 1 DM
[1–3], despite in type 2 DM only macroalbuminuria was
a significant risk factor in DR development [3].
The presence of diabetic retinopathy (DR) is easy to
establish through observable retinal lesions. However, dia-
betic renal lesion is more difficult to diagnose. Nondiabetic
nephropathy has a prevalence in DM patients that varies
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from different studies [4, 5] and difficult diagnosis of diabetic
nephropathy. Diabetic retinopathy is present in T1DM with
diabetic nephropathy [6]; on the contrary, type 2DM patients
can develop DN without diabetic retinopathy [7].
Also, current clinical guidelines differ, such as KDIGO
(Kidney Diseases: Improving Global Outcomes), who defines
chronic renal diseases as the presence of an estimated glo-
merular filtration rate inferior to 60ml/min/1.73m2 or renal
lesion that can be demonstrated from histological biopsy or
by the ratio of urine albumin to creatinine (UACR) [8].
The recent introduction of estimated glomerular filtra-
tion rate (eGFR) has become an easy method for studying
renal function, determined from serum creatinine, age, sex,
and race [9]. At present, we have two major formulae, the
equation of chronic kidney disease-epidemiology collabora-
tion (CKD-EPI) [10] and themodification of diet in renal dis-
ease (MDRD-4 or MDRD-IDMS) [11]. Both can help us to
determine renal function by a simple blood sample measure.
The CKD-EPI equation is more accurate, especially with glo-
merular filtrate between 60 and 90ml/min/1.73m2 [12].
As we have previously published studies on DR incidence
and its risk factors using data collected since 2007 from
our screening programme of 15,811 Caucasian, type 2 DM
patients [13], in the present study, we have the aim to deter-
mine whether there is a relationship between diabetic
nephropathy and incidence of diabetic retinopathy in type
2 DM patients.
2. Materials and Methods
2.1. Setting. The reference population in our health care area
(HCA) is 247,174 inhabitants. The current number of DM
patients registered in our HCA is 18,528.
2.2. Design and Sample. This is a prospective, population-
based study of 15,811 Caucasian, T2DM patients from data
collected between 1st January 2007 and 31st December
2016, with a mean follow-up of 3.45± 1.12 times for each
patient over the ten years. This includes 85.33% of T2DM
patients of our HCA; the rest of the patients did not attend
the screening, or they were lost during the study. Patients
have been screened in our nonmydriatic fundus camera units
(NMCU).
2.3. Power of the Study. Our epidemiologist evaluated
the T2DM sample and estimated the accuracy of 95% with
a ±3% increase in risk.
2.4. Method. Screening for DR was carried out with one 45°
field retinograph, centred on the fovea. If DR was evident,
another 2 retinographs of 45° were taken according to
EURODIAB guidelines. The complete method is described
elsewhere [14, 15].
In the present study, DR is thus classified as (i) no-
DR=no diabetic retinopathy, (ii) any-DR= level 20 to 35 of
the ETDRS, and (iii) STDR= level 43 or worse as defined
by the ETDRS. The term diabetic macular edema (DME)
includes extrafoveal and/or clinically significant macular
edema (CSMO) according to the ETDRS classification [16].
Measures of renal diabetes disease were determined by
(i) Serum creatinine, determined by molecular absorp-
tion spectrometry,
(ii) Estimated glomerular filtration rate (eGFR), calcu-
lated from plasma creatinine using chronic kidney
disease epidemiology collaboration equation (CKD-
EPI equation):
(1) For women
(a) creatinine< 0.7mg/dl eGFR=144× (creati-
nine/0.7)−0.329× (0.993)age
(b) creatinine> 0.7mg/dl eGFR=144× (creati-
nine/0.7)−1.209× (0.993)age
(2) For men
(a) creatinine> 0.9mg/dl eGFR=141× (creati-
nine/0.9)−1.209× (0.993)age
Gradation was expressed in ml/min/1.73m2 and
defined as normal = eGFR> 90, mildly diminishe-
d= eGFR 60–89, moderately diminished = eGFR
45–59, moderate–severely diminished = eGFR 30–
44, and severely diminished = eGFR< 30.
(iii) Ratio of urine albumin to creatinine (UACR). UACR
was collected from urine samples for measurement
of albumin and creatinine. Albumin was measured
in mg/l and creatinine in mmol/l. The concentration
ratio of urine to creatinine expressed in mg/g was
used to estimate the total daily albumin excretion.
UACR was classified as normoalbuminuria=
UACR<30mg/g, microalbuminuria as UACR 30–
299mg/g, and macroalbuminuria as UACR
≥300mg/g.
The diagnosis of diabetic nephropathy was made by
family physicians or endocrinologists, and according
to the diagnosis, we use two different definitions of
diabetic renal diseases:
(a) Chronic kidney disease is defined as UACR
≥ 30mg/g or eGFR< 60ml/min/1.73m2.
(b) Renal failure is defined as UACR≥ 300mg/g and
eGFR< 30ml/min/1.73m2.
At the end of the study in January 2017, all electronic
databases of patients were screened again to confirm
the number of patients with DR and if any new
patients had not previously been diagnosed.
2.5. Inclusion Criteria. Patients with all T2DM were screened
in our primary HCA.
2.6. Exclusion Criteria. Patients with other specific types of
diabetes and patients with gestational DM were excluded.
We followed our methods published by Romero-
Aroca et al. [17].
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2.7. Ethical Adherence. The study was carried out with the
approval of the local ethics committee (approval number
13-01-31/proj6) and in accordance with revised guidelines
of the Declaration of Helsinki. The study was approved and
supported by Instituto de Salud Carlos III (IISCIII), Spain
(FI12/01535, June 2013, and FI15/01150, July 15), and
FEDER fundus.
2.8. Statistical Methods. The epidemiological risk factors
included were as follows: current age, age at DM diagnosis,
gender, duration and treatment of DM, arterial hypertension,
levels of glycosylated haemoglobin (HbA1c), triglycerides,
cholesterol fractions, and mentioned renal disease measures.
Incidence was measured for each year of the study using
the following formula: patients with DR/all patients screened.
The ten-year sum incidence was calculated as number of
patients with DR over 10 years/subjects at risk.
Data evaluation and analysis was carried out using SPSS
22.0 statistical software package, and p < 0 05 was considered
to indicate statistical significance.
Descriptive statistical analysis of quantitative data was
made by determining mean, standard deviation, minimum
and maximum values, and the 95% confidence interval. For
qualitative data, we used the analysis of frequency and per-
centage in each category. Differences were examined using
the two-tailed Student t-tests to compare two variables or
using one-way ANOVA analysis of variance if we were com-
paring more than two variables. Inferential analysis for qual-
itative data was made by chi-squared table and by the Fisher
test for quantitative data.
Survival analysis was carried out using the following:
(i) The Kaplan-Meier curve measured the accumulated
risk of developing DR (in each of three forms: any-
DR, STDR, and DME) in patients with renal failure
using UACR≥ 300mg/g and using eGFR< 30ml/
min/1.73m2.
(ii) And the Cox proportional hazards model was used in
order to evaluate survival curves considering other
variables that may affect survival as age, sex, HbA1c,
arterial hypertension, and DM treatment.
In Cox’s survival analysis, we also applied four models:
(1) Without renal status inclusion; no eGFR nor UACR
included
(2) Including eGFR< 60ml/min/1.73m2 as variable
(3) Including UACR≥ 300mg/g as variable
(4) Including eGFR<60ml/min/1.73m2 and UACR≥
300mg/g as variable
3. Results
3.1. Demographic Variables of Sample Size. In the ten-year
follow-up (1 January 2007 to 31 December 2016), a total of
15,811 T2DM patients were screened (Table 1), which repre-
sents 85.33% of the total T2DM patients registered (18,528)
in our health care areas (HCAs), with a mean follow-up of
3.45± 1.12 times for each patient over the ten years.
The whole sample included more males (56.13%), which
does in fact reflect the prevalence of diabetes in the popula-
tion as a whole. The mean current age was 63.91± 11.85 years
and DM duration was 8.36± 6.64 years. Mean HbA1c values
were 7.41± 1.45% (3.9–15.8). Excluding differences in age,
men are more frequently being significant at p < 0 001.
Mean age of patients with any-DR was 63.91± 11.85
years, patients with STDR were 64.05± 12.27 years, and
patients with DME were 64.36± 12.84 years.
3.2. Study of Incidence of Diabetic Retinopathy. A total of
4466 patients with T2DM developed any-DR (28.24%),
with a mean annual incidence of 8.21± 0.60% (7.06%–
8.92%) (Table 2). STDR in T2DM was developed in 1451
patients (9.17%) with an annual incidence of 2.65± 0.14%
(2.48%–2.88%). DME in T2DM was developed in 1214
patients (7.67%) with an annual incidence of 2.21± 0.18%
(2%–2.49%).
3.3. Study of Incidence of Nephropathy. A total of 3767
patients (23.82%) with T2DM had UACR> 30mg/g with a
mean annual incidence of 7.02± 0.05% (6.97%–7.09%)
(Table 2). A total of 3173 patients had eGFR< 60ml/min/
1.73m2 (20.06%) with an annual incidence of 5.89± 0.12%
(5.70%–6.13%). Finally, 36 patients (0.22%) had renal failure,
defined as UACR≥ 300mg/g and eGFR< 30ml/min/1.73m2
in T2DM, with an annual incidence of 0.06± 0.01% (0.04%–
0.08%).
3.4. Statistical Analysis of any Diabetic Retinopathy. At the
end of the study, all T2DM patients visited our unit and a
fundus examination was carried out. We did not find any
new patients with DR. We confirm, therefore, that no
patient had been misdiagnosed during the screening pro-
gramme. In the univariate analysis (Table 3), all studied var-
iables are significant.
When we applied Cox’s proportional regression analysis
(Table 4), the variables studied in univariate analysis changed
significance; thus, in the first model, current age, insulin
treatment, arterial hypertension, and HbA1c levels sex were
significant. The introduction of renal function causes new
changes. The eGFR was significant in the second model
(p = 0 002, HR 1.854), but when we introduced UACR
in the third model, it became less significant (p = 0 05,
HR 1.123). Finally, the inclusion of renal failure in the
fourth model, defined as UACR≥ 300mg/g and eGFR<
30ml/min/1.73, was significant at the same level as the
UACR value.
3.5. Statistical Analysis of Severe Diabetic Retinopathy Forms.
Table 5 shows descriptive data of different risk factors and its
significance. In STDR, current age, DM duration, HbA1c
levels, UACR, and eGFR are significant in two-tailed
Student’s t-test or using one-way ANOVA analysis of vari-
ance, but creatinine levels are not significant. Similarly, in
the DME study, all previously described risk factors are sig-
nificant in its development.
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Table 1: Descriptive and frequency values of the sample.
Year








Mean level of HbA1c % mean± SD
(min–max)
2007 4910 2881 (57.31) 64.62± 12.23 8.37± 6.92 7.37± 1.48 (3.9–14)
2008 4873 2802 (56.16) 66.27± 12.32 8.66± 6.78 6.82± 1.24 (4.3–12)
2009 5191 2890 (54.41) 65.39± 12.41 8.57± 6.12 7.02± 1.7 (3.8–15)
2010 5243 3007 (56.03) 65.69± 11.7 8.23± 6.81 7.47± 1.5 (4.5–14.5)
2011 5264 2933 (55.60) 65.22± 12.12 8.29± 6.56 7.3± 1.5 (4–15.5)
2012 6193 3594 (56.72) 65.33± 12.08 8.23± 6.82 7.63± 1.4 (4.3–15.8)
2013 5494 3131 (55.69) 65.87± 12.07 8.28± 6.11 7.62± 1.41 (4.3–15.8)
2014 5983 3511 (57.33) 65.88± 11.94 8.34± 6.83 7.64± 1.4 (4–15.6)
2015 5026 2817 (56.05) 65.84± 12.39 8.35± 6.77 7.61± 1.5 (4.2–15)
2016 5423 3036 (56) 65.94± 12.27 8.32± 6.72 7.63± 1.4 (4.4–15.4)
Descriptive values are presented as number or mean ± standard deviation (SD).













eGFR< 30ml/min/1.73m2, n (%)
2007 390 (7.94) 131 (2.6) 104 (2.00) 294 (5.98) 343 (6.98) 3 (0.06)
2008 384 (7.88) 125 (2.5) 101 (2.02) 290 (5.95) 344 (7.06) 2 (0.04)
2009 411 (7.06) 132 (2.48) 112 (2.11) 301 (5.79) 363 (6.99) 3 (0.06)
2010 424 (8.05) 134 (2.49) 114 (2.12) 309 (5.89) 372 (7.09) 4 (0.07)
2011 407 (7.73) 141 (2.67) 110 (2.08) 310 (5.89) 368 (6.99) 4 (0.07)
2012 533 (8.6) 170 (2.68) 150 (2.36) 353 (5.70) 432 (6.97) 4 (0.06)
2013 489 (8.9) 162 (2.88) 135 (2.40) 324 (5.89) 390 (7.09) 4 (0.07)
2014 529 (8.84) 174 (2.84) 153 (2.49) 357 (6.13) 419 (7.01) 5 (0.08)
2015 415 (8.25) 139 (2.76) 122 (2.42) 301 (5.98) 351 (6.98) 4 (0.07)
2016 484 (8.92) 144 (2.65) 114 (2.10) 314 (5.79) 385 (7.09) 3 (0.05)
Table 3: Statistical analysis at the end of the ten-year follow-up study.
Variables Category Mean values Univariate statistical study significance
Age (years)
No diabetic retinopathy 62.53± 13.63
p < 0 001, (F = 6 998)∗
Diabetic retinopathy 71.94± 10.56
Sex (male)
No diabetic retinopathy 41.50%
p < 0 001, OR 2.24 (1.05–3.22)∗∗
Diabetic retinopathy 58.50%
Diabetes duration (years)
No diabetic retinopathy 9.36± 6.58
p < 0 001, (F = 21 56)
Diabetic retinopathy 12.18± 6.21
Arterial hypertension
No diabetic retinopathy 49.53
p = 0 003, OR 2.04 (1.14–3.11)
Diabetic retinopathy 50.47
Insulin treatment
No diabetic retinopathy 18.54
p < 0 001, OR 3.98 (2.24–5.17)
Diabetic retinopathy 51.40
HbA1c (%)
No diabetic retinopathy 7.69± 2.69
p < 0 001, (F = 13 75)
Diabetic retinopathy 8.07± 1.76
eGFR (ml/min/1.73m2)
No diabetic retinopathy 89.66± 16.11
p = 0 004, (F = 9 10)
Diabetic retinopathy 56.32± 12.20
UACR (mg/g)
No diabetic retinopathy 4.82± 43.00
p < 0 001, (F = 14 81)
Diabetic retinopathy 75.30± 231.26
∗Study made with two-tailed Student’s t-test or ANOVA; F: Fisher-Snedecor distribution. ∗∗Study made with Chi-square; OR: odds ratio (95% CI).
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Table 6 shows significance of different variables in Cox’s
analysis. In STDR patients, all risk factors are significant in
model 1, according to the hazard ratio HbA1c, UACR and
arterial hypertension are important risk factors. In model 2
of STDR study, we substituted eGFR< 60ml/min/1.73m2
and UACR≥ 30mg/g for renal failure, defined as
UACR≥ 300mg/g and eGFR< 30ml/min/1.73m2, which
become an important risk factor with a hazard ratio of
3.174, like the hazard ratio of 3.230 of HbA1c.
The study of diabetic macular edema also demonstrated
that all risk factors are significant in model 1, and HbA1c
level, arterial hypertension, and UACR have the highest haz-
ard ratio values. Also, the substitution of eGFR< 60ml/min/
1.73m2 and UACR> 30mg/g for renal failure becomes an
important risk factor for DME development with a hazard
ratio of 3.190 like 3.194 hazard ratio of HbA1c.
3.6. Study of Survival Analysis. In this paragraph, we com-
pared survival study made with Kaplan-Meier product-limit
graph and Cox proportional hazards model. In Figures 1
and 2, we show the accumulated risk of developing diabetic
retinopathy in each of the three studied categories.
Figure 1 used the Kaplan-Meier product-limit graph to
evaluate the relationship between renal failure diagnosed by
UACR or eGFR in each DR type. Using the plots risk func-
tion, it is evident that UACR≥ 300mg/g increases signifi-
cantly the accumulated risk of any-DR, STDR, and DME
along with DM duration. The use of eGFR< 30ml/min/
1.73m2 as a diagnosis of renal failure is not reliable as an
indicator of an increased risk of STDR and DME, and a
significant link appeared only if we studied all patients with
any-DR.
Figure 2 shows the accumulated risk of DR using the Cox
proportional hazards model. At the top of the figure, we
observe an increased accumulated risk of development of
any-DR, STDR, and DME in patients with renal failure using
UACR≥ 300mg/g as method of diagnosis. On the contrary,
below that, we observe that renal failure diagnosis using the
Table 4: Multivariate analysis using Cox’s proportional regression analysis of any-diabetic retinopathy.
Variables Model 1∗ Model 2∗∗ Model 3∗∗∗ Model 4∗∗∗∗
Current age
p < 0 001 p < 0 001 p < 0 001 p < 0 001
HR 1.136 (1.084–1.224)† HR 1.140 (1.081–1.227) HR 1.140 (1.072–1.284) HR 1.145 (1.083–1.290)
Sex
p = 0 065 p = 0 077 p = 0 070 p = 0 073
HR 0.761 (0.643–0.961) HR 0.822 (0.668–1.060) HR 0.820 (0.651–1.072) HR 0.834 (0.644–1.015)
Insulin treatment
p < 0 001 p < 0 001 p < 0 001 p < 0 001
HR 1.218 (1.131–1.448) HR 1.302 (1.188–1.506) HR 1.311 (1.174–1.501) HR 1.302 (1.178–1.545)
Arterial hypertension
p = 0 05 p = 0 05 p = 0 045 p = 0 049
HR 1.118 (0.985–1.788) HR 1.121 (0.907–1.340) HR 1.134 (1.002–1.161) HR 1.367 (1.062–1.899)
HbA1c
p < 0 001 P < 0 001 p < 0 001 p < 0 001
HR 2.135 (1.893–2.408) HR 2.089 (1.811–2.632) HR 2.052 (1.780–2.273) HR 2.037 (1.806–2.297)
eGFR< 60ml/min/1.73m2
p = 0 002 p = 0 04 p = 0 09
HR 1.854 (1.251–4.431) HR 1.223 (1.098–1.201) HR 1.103 (0.078–1.311)
UACR≥ 30mg/g
p < 0 001 P = 0 004
HR 1.485 (1.103–1.548) HR 1.485 (1.092–1.465)
UACR≥ 300mg/g and
eGFR< 30ml/min/1.73m2
p < 0 001
HR 1.998 (1.682–2.305)
Model 1∗, Cox’s analysis in which the variables of renal function are not included; model 2∗∗, Cox’s analysis in which we include only the eGFR variable for the
study of renal function; model 3∗∗∗ , Cox’s analysis with eGFR and UACR as variables for the study of renal function; model 4∗∗∗∗, Cox’s analysis in which we
included in addition to the eGFR and the UACR, the presence of renal failure. †Hazard ratio (95% CI).
Table 5: Descriptive data of diabetic retinopathy forms.
No-DR STDR Significance DME Significance
Current age (years) 64.01± 13.99 64.05± 12.27 p = 0 005, F = 5 306 64.36± 12.84 p = 0 002, F = 6 401
DM duration (years) 8.71± 6.12 13.91± 7.85 p < 0 001, F = 26 141 13.77± 7.78 p < 0 001, F = 25 788
HbA1c (%) 7.33± 1.76 9.21± 1.97 p < 0 001, F = 29 033 9.18± 1.96 p < 0 001, F = 28 867
eGFR (<60ml/min/1.73m2) 85.69± 20.31 73.32± 24.09 p = 0 01, F = 8 494 73.17± 24.20 p = 0 01, F = 8 568
UACR (>30mg/g) 3.25± 55.33 66.68± 172.56 p < 0 001, F = 14 640 67.06± 173.78 p < 0 001, F = 14 665
STDR: sight threatening diabetic retinopathy; DME: diabetic macular edema; F = Fisher-Snedecor distribution.
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eGFR< 30ml/min/1.73m2 was not significant for any of
three types of DR. It is interesting that using the Kaplan-
Meier curve, any-DR had an increased accumulative risk,
but in the Cox’s survival analysis, after the introduction of
the other risk variables (age, sex, arterial hypertension, and
HbA1c), the effect disappeared and became not significant.
4. Discussion
The present study should be taken in the context of previous
studies [13, 17] conducted on the same population. Incidence
of any-DR at the ten-year follow-up was 28.24% with a mean
annual incidence of 8.21± 0.60% (7.06%–8.92%), similar to
previously published data. Referable DR described as STDR
had an annual incidence of 2.65± 0.14% (2.48%–2.88%),
and DME had an annual incidence of 2.21± 0.18% (2%–
2.49%); both results are similar to those of The Scottish
National Diabetic Retinopathy Screening Programme [18].
A particularly interesting result from our study is that STDR
incidence at ten years was 1451 patients (9.17%), and DME
affected 1214 patients (7.67%), but only 237 patients had
STDR without DME, representing 16.33% of patients with
STDR. We should take into account that STDR might be
due to DME or ischemic retina secondary to severe DR
and conclude that only 1.50% of patients in our study devel-
oped STDR without DME. Due to this little difference in
incidence between STDR and DME patients, the two groups
have similar results according to risk factors and numerical
statistical data.
For diabetic nephropathy (DN), with UACR≥ 30mg/g,
there was 23.82% of patients who developed DN at the end
of study, with a mean annual incidence of 7.02± 0.05%
(6.97%–7.09%). On the contrary, with eGFR< 60ml/min/
1.73m2, there was 20.06% patients with DN at the end of the
study, with a mean annual incidence of 5.89± 0.12% (5.70%–
6.13%). These discrepancies can be explained because glomer-
ular filtration rate increases in initial diabetic renal failure and
then reduces in most advanced nephropathy.
Statistical analysis shows that glomerular filtration was a
significant risk factor for DR and can be a predictive factor
for severe DR complications, as defined in our study as STDR
and DME. However, introducing UACR as a risk factor in the
equation in Cox’s survival analysis, the eGFR became less sig-
nificant; therefore, in the development of any-DR, the HR
decreases from 1.854 to 1.223, with a change in significance
from p = 0 002 to p = 0 04; Figures 1 and 2 clearly show this
effect. When we use the Kaplan-Meier curve, the eGFR is a
significant risk, but with the introduction of the other vari-
ables of age, sex, arterial hypertension, and HbA1c in the
Cox’s survival analysis, the effect of eGFR disappeared and
UACR is the only effective risk factor. We can conclude,
therefore, that UACR has greater relationship with DR devel-
opment than eGFR does.
The study of STDR and DME also shows that UACR
is a more significant risk factor than eGFR, despite eGFR
being an important risk factor, with HR having similar
values to other variables like arterial hypertension or insu-
lin treatment.
We can explain that eGFR is a less significant risk factor
than UACR in two ways. Firstly, changes in eGFR occur prior
to an increase in UACR, increasing its filtration ratio in the
early stage of diabetes mellitus and then reducing in
advanced stages, reflecting the decline in renal function. Sec-
ondly, arteriosclerosis, which can be developed in parallel to
diabetes, can decrease the glomerular filtration rate in
patients with normoalbuminuria [19]. Both mechanisms
can act as confounding factors in statistical results.
The greater significance of UACR in type 2 DM com-
pared with type 1 DM (T1DM), which we encountered in a
previous study with a series of T1DM patients [17], might
be explained by the different methodologies used.
In another previously published study [20], we reported
low significance of microalbuminuria as risk factor for DR
in T2DM, but in the same study, we encountered significant
values of albuminuria≥ 300mg/g and DR development.
Again, this might be due to the different methodology and
the fact that the previous study was a cross-sectional feature
rather than a prospective ten-year follow-up as this present
study is. In previous study, we defined microalbuminuria as
30–299mg/g, and in the present study, we defined renal
Table 6: Multivariate analysis using Cox’s proportional regression

























































∗Hazard ratio (95% confidence interval). STDR: sight threatening diabetic
retinopathy; DME: diabetic macular edema. ∗Hazard ratio (95%CI).
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nephropathy if UACR was up 30mg/g, which includes
patients with microalbuminuria and macroalbuminuria.
Our results can be compared, though with caution, with
similar published studies. Man et al. [21], in a case series
study of 263 Caucasian patients, found a link between
impaired renal function, measured by the CKD-EPI equation
and severe forms of DR, but not with DME. However, as
those authors said, perhaps its lower number of patients with
DME can lower the significance of the results, whereas our
study has a greater sample of patients (1214 patients with
DME), which might highlight its significance.
Wu et al. [22] reported that levels of eGFR less than or
equal to 99.4ml/min/1.73 were significant for DR in a
case-control hospital-based study. The present study consid-
ered only levels of eGFR less than 60ml/min/1.73 as patho-
logic, because, as we have said, glomerular filtration
increases in early stages of renal malfunction and can con-
found the results.
Most similar to our results are those reported by
Rodríguez-Poncelas et al. [23], who carried out a cross-
sectional study based on 28,344 patients. They demon-
strated that prevalence of DR increases in patients with
UACR≥ 300mg/g with and odds ratio of 2.0 and with a
positive relation between the decrease in eGFR and STDR.
The present study also demonstrates that eGFR is a less
significant risk factor than UACR.
Other studies used themodification of diet in renal disease
(MDRD-4 or MDRD-IDMS) [11] to determine eGFR. López
et al. [24], in a cross-sectional study, used the MDRD-4 for-
mula. Their results are similar to ours with a significance at
p < 0 001, OD=2.0, and 95%IC=1.6–2.4 in a clinical series
of 14,266 patients. Despite MDRD only being able to be used
as an alternative to the CKD-EPI equation, some publica-
tions currently estimate that the latter provides a more accu-
rate estimate of the eGFR [12, 25, 26].
The strengths of our study are the screening programme
itself, which had included an 85.33% of T2DM patients in our
HCA, and the ten-year follow-up of our T2DM population,
yielding a large amount of data.
The limitations of our study are that we determined
the CKD-EPI equation using creatinine data. Despite
serum creatinine measurements being carried out in the
same clinical laboratory, which used integrated database
management system-traceable samples to minimize calibra-
tion bias, it can cause errors in determination. Also,
patients with STDR, and/or DME, can be visited in hospi-
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Figure 1: Plots of risk function of Kaplan-Meier study. The y-axis represents the accumulative risk to develop diabetic retinopathy, and the x-
axis represents diabetes mellitus duration in years. The green curve represents effect of patients with renal failure as risk factor, and the blue
curve patients without renal failure. At the top, there is the analysis of renal failure measured with UACR≥ 300mg/g, and at bottom
eGFR< 30ml/min/1.73m2.
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5. Conclusions
In conclusion, the present study has shown that UACR have
higher association than eGFR with diabetic retinopathy and
its severe forms. From our data, we would encourage further
studies to determine the glomerular filtration rate and the
relationship of DR in T2DM patients as risk factor.
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